Old Web
Effect of Empagliflozin on Heart Failure–Related Events in Symptomatic Patients
2021
The industry-funded EMPEROR-Preserved trial (NCT03057951) demonstrated a significant benefit of the sodium–glucose cotransporter-2 inhibitor (SGLT-2i)
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI